To be clear, I believe vaccines and antiviral drugs BOTH have critical parts to play in the fight against #COVID19.
Oral antivirals are of particular interest given their potential for equitable distribution.
This is NOT an argument against antivirals.
2/15
-
-
Show this thread
-
Antivirals can work via several mechanisms.
PROTEASE INHIBITORS, like #paxlovid and#masitinib, prevent the production of mature viral proteins.
MUTAGENS, like #molnupiravir, instead increase the viral mutation rate to intolerable levels, causing LETHAL MUTAGENESIS. 3/15Show this thread -
Critically, any self-administered drug risks low concentrations due to missed doses, incomplete courses, or low initial penetrance. For
#molnupiravir, this might induce only SUBLETHAL MUTAGENESIS, accelerating within-host virus evolution and potentiating new variants. 4/15Show this thread -
The risk of mutagens is underscored by the fact that another antiviral,
#ribavirin, induces adaptive mutations in other RNA viruses. Moreover, past#SARSCoV2 variants of concern likely acquired adaptive combinations of mutations during chronic infections before transmitting. 5/15Show this thread -
Given the potential for SUBLETHAL MUTAGENESIS of
#SARSCoV2 by#molnupiravir, steps should be taken to understand the evolutionary consequences of low drug concentrations and improper administration for pathogen evolution. Below is a list of issues to consider.
6/15Show this thread -
Because #molnupiravir will be taken by patients with recent symptom onset, and drug concentration increases from 0 over time, PEAK VIRAL SHEDDING is likely to occur while drug concentration is still low. This could potentiate the shedding of mutant — but viable — virus. 7/15Show this thread -
#Molnupiravir has a SHORT PLASMA HALF-LIFE, making low concentrations easier to achieve, say, as a result of missed or inconsistently timed doses. 8/15Show this thread -
Coronaviruses have a propensity for RECOMBINATION, which can help purge viral genomes of deleterious mutations, or generate adaptive combinations of beneficial or compensatory mutations. These phenomena are therefore critical to include in models and simulations.
9/15Show this thread -
#SARSCoV2 has a PRE-EXISTING BIAS for C→U mutations — the main mutation caused by#molnupiravir — as well as a genomic G:C content of 38%, and a plus-strand C content of 18%. These characteristics limit the extent to which molnupiravir can raise the mutation rate. 10/15Show this thread -
Epidemiological spread of adaptive mutations is limited by both:
(a) their GENERATION VIA MUTATION within hosts; and
(b) the TRANSMISSION BOTTLENECK SIZE between hosts, that is, the number of viral genomes that found a new infection.
11/15Show this thread -
Even if the average number of mutations per viral genome is high, the DISTRIBUTION OF MUTATION COUNTS can still include a class of minimally mutated viable genomes. This could be due to the mutation mechanism or ‘compartments’ with low drug concentrations within a host.
12/15Show this thread -
The MUTATIONAL ROBUSTNESS of #SARSCoV2 is not known. The highest mutation rate tolerated by a virus, just possibly 1-5 per replication per genome, depends on the size of the functional genome and the expendability of ‘accessory’ genes. 13/15Show this thread -
EVERYONE must understand the importance of taking
#molnupiravir as directed, and of quarantining while doing so, as the above issues are studied. We must ensure that#SARSCoV2 is not inadvertently handed mutational resources for the accelerated generation of new variants. 14/15pic.twitter.com/23x0Cmow4z
Show this thread -
THANKS to coauthor @sarperotto and all who generously gave feedback:@zachary_ardern,@AprilWei001,@GoldbergTony,@jbloom_lab, and@RJABuggs, who first raised this issue to me on October 6 and provided invaluable insight and edits. All views and any errors are our own. 15/15Show this thread -
UPDATE on #MOLNUPIRAVIR. Below is a review of the@US_FDA materials and November 30 panel discussion on the potential for this drug to cause new#SARSCoV2 variants of concern. Overall, the panel voted in favor of authorization, 13 YES
to 10 NO
.
https://twitter.com/chasewnelson/status/1466331830345293827 …Show this thread -
Some conceptual figures illustrating our concerns are here
https://twitter.com/chasewnelson/status/1466722854876377093 …
Show this thread -
Additional insights from
@LauringLab and others on whether the mutation-inducing antiviral#molnupiravir could accelerate#SARSCoV2 variants of concern
https://twitter.com/chasewnelson/status/1468164091814748161 …Show this thread -

UPDATE on #Molnupiravir: paper out in@NEJM. One sentence addresses the concern that its poorly characterized mutagenicity could accelerate virus evolution: "The mechanism of action of molnupiravir is independent of mutations in the spike protein..." https://twitter.com/NEJM/status/1471604809396482048 …pic.twitter.com/mKfMYy3vSI
Show this thread -
It is correct that the drug should work the same regardless of Spike genotype. A false interpretation is that molnupiravir doesn't mutate Spike. It does, along with the rest of the genome. Thus, I believe we still have only two relevant data summaries from Merck:
Show this thread -
Merck reports a mean of ~7.5 mutations at a within-patient frequency of >5% across the virus genome.
Note the range includes *0*. Note too this is within-host diversity (polymorphism) filtered by selection, not a mutation rate.pic.twitter.com/HE3xdk17e9
Show this thread -
Merck provides this chart, also difficult to interpret, but again likely referring to within-host variants at >5% frequency. Note that Baseline and Day 5 distributions *overlap*.
More is needed, including raw sequence data, to estimate virus mutation and onward transmission.pic.twitter.com/P1OJgGwwjj
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
•
• views my own • 



1/15
section 4.3.2.5 (pp. 30-36)

at 2h51m, 3h46m, 4h5m, 5h12m, 7h32m